Roundtable Roundup: Bladder Cancer

Publication
Article
Peers & Perspectives in OncologyFebruary 2025
Pages: 76

In separate, live virtual events, David H. Aggen, MD, PhD; and Matthew R. Zibelman, MD, discussed the case of a patient with urothelial carcinoma and potential treatment options.

CASE SUMMARY


A man aged 74 years presents to his primary care physician reporting intermittent episodes of painless macrohematuria.

History

  • Stage 3a chronic kidney disease; type 2 diabetes
  • New York Heart Association heart failure grade 2
  • Medications: empagliflozin once daily; enalapril once daily
  • Mild chronic obstructive pulmonary disease
  • Tobacco history: current smoker, 20 pack-years
  • Retired textile chemist

Focused Physical Exam

  • ECOG performance status: 1
  • Pulmonary: diminished lung sounds, inspiratory rhonchi, expiratory wheezing on auscultation

Evaluation by Urologic Oncologist

  • History of renal insufficiency: cisplatin-ineligible
  • Arterial portography MRI and magnetic resonance urography:
    • Nodular, 6-cm lesion within the left, posterior bladder wall invasive into inner half of muscularis propria
    • No renal parenchymal masses
    • Enlarged single, regional, obturator node, measuring 8 mm
    • No evidence of lymph node involvement or hepatic metastasis
  • Chest CT without metastasis
  • White light cystoscopy and barbotage detected single, penetrating lesion along right lateral bladder wall
    • Bladder wash samples and multiple tissue specimens obtained
  • Cytohistopathology: N:C ratio > 0.7; nuclear pleomorphism; moderate to severe hyperchromasia
  • High-grade urothelial carcinoma
map
poll-bladder cancer

REFERENCE

1. Galsky MD, Witjes JA, Gschwend JE, et al. Adjuvant nivolumab in high-risk muscle-invasive urothelial carcinoma: expanded efficacy from CheckMate 274. J Clin Oncol. 2025;43(1):15-21. doi:10.1200/JCO.24.00340

Recent Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content